NCT03083431 Ongoing.

Trial name or title	Propranolol for prevention of threshold retinopathy of prematurity (ROPROP).
Methods	Randomised, placebo‐controlled trial.
Participants	Extremely preterm infants.
Interventions	Oral propranolol 1.6 mg/kg/d in 4 divided doses or placebo given for 4 to 10 weeks.
Outcomes	Primary outcome: survival until 48 weeks' PMA without ≥ stage 3 ROP.
Starting date	2018
Contact information	christoph.buehrer@charite.de, roman.weimann@charite.de
Notes	Phase 2 interventional study